Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03144271
Recruitment Status : Completed
First Posted : May 8, 2017
Last Update Posted : May 8, 2017
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:
This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability of ascending single s.c. doses of NNC 0113-0217 in healthy male subjects, aiming at establishing the Maximum Tolerated Dose (MTD)

Condition or disease Intervention/treatment Phase
Diabetes Diabetes Mellitus, Type 2 Healthy Drug: semaglutide Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 58 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled, Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects
Actual Study Start Date : June 11, 2007
Actual Primary Completion Date : October 8, 2007
Actual Study Completion Date : October 8, 2007

Arm Intervention/treatment
Experimental: NNC 0113-0217
Dose-escalation trial
Drug: semaglutide
A single dose of 0.625, 1.25, 2.5, 5, 10, 20, 40 or 80 μg/kg semaglutide will be administered subcutaneously (s.c. under the skin).
Other Name: NNC 0113-0217

Placebo Comparator: Placebo
Dose-escalation trial
Drug: Placebo
A single dose of placebo will be administered subcutaneously (s.c. under the skin)




Primary Outcome Measures :
  1. Number of Adverse Events [ Time Frame: After 24-33 days ]

Secondary Outcome Measures :
  1. Area under the curve of NNC 0113-0217 [ Time Frame: From 0-48 hours after dosing ]
  2. Area under the curve of NNC 0113-0217 [ Time Frame: From 0-168 hours after dosing ]
  3. Morning fasting plasma glucose [ Time Frame: At visit 1 (days -28 to -1), 2 (days 0-8), 3 (days 11-13) and 4 (days 17-19) ]
  4. Morning fasting insulin [ Time Frame: At visit 1 (days -28 to -1), 2 (days 0-8), 3 (days 11-13) and 4 (days 17-19) ]
  5. Morning fasting glucagon [ Time Frame: At visit 1 (days -28 to -1), 2 (days 0-8), 3 (days 11-13) and 4 (days 17-19) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject)
  • Subject is male
  • Age 18-65 years, both included
  • Body Mass Index (BMI) below 35.0 kg/m^2 (Body weight between 50 kg -150 kg, both inclusive)
  • Good general health based on medical history, physical examination including ECG (Electrocardiogram) and laboratory analysis, as judged by the investigator

Exclusion Criteria:

  • Previous participation, defined as randomised, in any other clinical trial involving this or other investigational products within the last 3 months before dosing
  • Patients with MI (Myocardia-Infarction) during the last 12 month
  • Patients receiving ACE (Angiotensin-Converting Enzyme) inhibitors, beta-blockers, thiazide diuretics, thyroid hormones, and/or lipid lowering medication who are not on a stable dose for more than 6 weeks prior to start of the study
  • Use of weight lowering medications (orlistat, sibutramine, rimonabant, phentermine)
  • Clinically significant GI (Gastro-Intestinal) disease including inflammatory bowel disease, irritable bowel syndrome, celiac disease, dyspepsia, apparent diabetic gastro paresis, diabetic diarrhoea, or surgery of the gastro-intestinal tract (except appendectomy and cholecystectomy)
  • Subjects who are sexually active and have not been surgically sterilised must be informed that they and their partner use a highly effective method of contraception (Pearl Index below 1%) such as implants, injectables, combined oral contraceptives, or hormonal IUDs (intrauterine devices), or refrain from sexual intercourse during the study and until 1 month after completion of the trial. This is to prevent the possibility of a pregnancy from spermatocytes that can potentially be damaged by study medication
  • Current treatment with drugs known to interfere with glucose metabolism such as systemic corticosteroids, non-selective beta-blockers, and MAO (Mono-Amino-Oxidase) inhibitors
  • Subjects who drink more than 8 cups of tea/coffee per day
  • History of drug or alcohol abuse (defined as intake of more than 28 units weekly - 1 unit = 12 oz or 360 ml of beer; 5 oz ir 150 ml of wine; 1.5 oz or 45 ml of distilled spirits)
  • Alcohol intake within 48 hours prior to dosing
  • Evidence of drug abuse on urine testing and serum at study entry
  • The subject smokes 7 cigarettes or more, or the equivalent, per day and is unable to refrain from smoking during 3 days prior to the dosing day and during the confinement period
  • Hepatitis B surface antigen (HBsAg), Hepatitis C antibodies or HIV-positive
  • Impaired hepatic function measured as ALAT (Alanine aminotransferase), ASAT (Aspartate aminotransferase), alkaline phosphatase above three times the upper reference limit (one retest within one week is permitted, the last result being conclusive)
  • Clinical significant abnormal laboratory test results during the screening as judged by the Investigator
  • Impaired renal function, defined as s-creatinine above or equal to 135 μmol/L (=1.5mg/dL) (one retest within one week is permitted, the last result being conclusive)
  • Cardiac problems defined as: decompensated heart failure (NYHA (New York Heart Association) class III and IV) at any time and/or angina pectoris and/or myocardial infarction within the last 12 months
  • Blood pressure in supine position at the screening examination above 160 mmHg systolic or 90 mmHg diastolic or heart rate outside the range of 50 - 90 bpm
  • Known or suspected allergy to trial product or related products
  • History of significant drug allergy or drug hypersensitivity
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
  • Blood donation or considerable blood loss - more than 500 mL, during the 3 months prior to study start
  • Any condition that the investigator and / or sponsor feels would interfere with study participation or evaluation of results
  • Use of non-prescription drugs, except routine vitamins, within 1 week prior to the dose of the test drug. Occasional use of paracetamol is permitted
  • Subjects who have taken part in strenuous exercise within 4 days prior to trial start, due to interference with the hepatic microsomal mono-oxygenase system. The evaluation whether strenuous exercise has been undertaken will be evaluated by the Investigator, and strenuous exercise is not allowed during the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03144271


Locations
Layout table for location information
Germany
Novo Nordisk Investigational Site
Neuss, Germany, 41460
Sponsors and Collaborators
Novo Nordisk A/S
Additional Information:
Layout table for additonal information
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT03144271    
Other Study ID Numbers: NN9535-1820
2007-000303-15 ( EudraCT Number )
U1111-1193-6996 ( Other Identifier: World Health Organization (WHO) )
First Posted: May 8, 2017    Key Record Dates
Last Update Posted: May 8, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases